Boehringer Mannheim Gmbh

Other

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Wilex Biotechnology Gmbh

Wyeth

Immunex Corporation

Max-planck-institute for Biochemistry

Wolfram Bode

Robert Huber

Luis Moroder

Erhard Kopetzki

Richard Engh

Karl-Peter Hopfner

Olaf G Wilhelm

Viktor Magdolen

Thomas Martin

Stefan Sperl

Josef Stadlwieser

Uwe Jacob

Wolf-R&uuml;diger Ulrich

Joerg Stuerzebecher

Thomas B&auml;r

Ulrich Thibaut

Rolf Beume

Christian Sommerhoff

Norbert Schaschke

Andreas Bergner

Pedro Jose Barbosa Pereira

Andreas Dominik

Karl-Josef Goebel

Daniela Bundschuh

Nuria Arroyo De Prada

Jeremy Ian Levin

James Ming Chen

Raymond J Paxton

Roy A Black

Klaus Maskos

Carlos Fernandez-Catalan

A method is described for inhibiting urokinase plasminogen activator in a human or animal patient. The method involves administering to the patient a urokinase plasminogen activator inhibiting effective amount of a compound of the formula (I): 

Highly selective inhibitors of the urokinase plasminogen activator

A tumor necrosis factor-&#x3b1; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.

Crystalline TNF-&#x3b1;-converting enzyme and uses thereof

The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.

A chimeric serine protease whose protease domain is composed of two domain halves (half-sides) with a &bgr;-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

Chimeric serine proteases

Tryptase inhibitors

The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments.

A chimeric serine protease whose protease domain is composeD. of two domain halves (half-sides) with a &bgr;-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

A chimeric serine protease whose protease domain is composed of two domain halves (half-sides) with a .beta.-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

Growing community of inventors

Gauting, Germany

Wolfram Bode